Biocept Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Antonino Morales
Chief executive officer
US$781.6k
Total compensation
| CEO salary percentage | 46.8% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3.9yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth
Apr 17
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position
Nov 23Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings
Aug 19Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being
Jul 03Biocept and CLEARED4 ink collaboration agreement
Jun 09Biocept enters COVID-19 testing partnership
Apr 28Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain
Mar 13We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate
Jan 26
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?
Dec 22Biocept's assays viable and sensitive for detecting tumor cells and biomarkers
Nov 20Biocept +4% on COVID-19 testing update
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$782k | US$366k | -US$32m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$57k | n/a | -US$3m |
Compensation vs Market: Antonino's total compensation ($USD781.63K) is about average for companies of similar size in the US market ($USD738.70K).
Compensation vs Earnings: Antonino's compensation has increased whilst the company is unprofitable.
CEO
Antonino Morales (67 yo)
less than a year
Tenure
US$781,631
Compensation
Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$781.63k | no data | |
| Chief Legal Officer | 1.7yrs | US$773.28k | 0% $ 0 | |
| Founder | 26.8yrs | no data | no data | |
| VP & Controller | less than a year | no data | no data | |
| Chief Operating Officer | 1.6yrs | no data | no data | |
| Director of Technology Development | 6.1yrs | no data | no data | |
| Vice President of Strategy & Corporate Communications | 7yrs | no data | no data | |
| Senior Medical Director | 8.8yrs | US$577.58k | no data |
3.9yrs
Average Tenure
59yo
Average Age
Experienced Management: BIOC's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.3yrs | US$781.63k | no data | |
| Independent Director | 13.8yrs | US$65.21k | 0.000080% $ 2.1 | |
| Independent Director | 2.3yrs | US$57.26k | 0% $ 0 | |
| Independent Director | less than a year | US$13.32k | 0% $ 0 | |
| Independent Vice Chairman of the Board | 9.9yrs | US$70.21k | 0.000040% $ 1.1 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 13yrs | US$67.71k | 0.00057% $ 15.3 |
6.1yrs
Average Tenure
72yo
Average Age
Experienced Board: BIOC's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/15 05:25 |
| End of Day Share Price | 2023/10/13 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocept, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Sally Yanchus | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |